SCHEMBL10140272

SCHEMBL10140272

COc1ccc(COc2c(-c3ccccc3)nn(Cc3ccc(OC)cc3)c2C(C)=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
PTGER4 P35408 2/20 0.46
FAAH O00519 1/20 0.45
MGLL Q99685 1/20 0.45
AKR1C3 P42330 2/20 0.45
NPBWR1 P48145 1/20 0.44
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.43
SLC16A3 O15427 2/20 0.43
SLC16A1 P53985 2/20 0.43
MCTS1 Q9ULC4 2/20 0.43
KCNK3 O14649 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140278 0.92 SMN1; SMN2 (0.48) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL8890615 0.84 HTT (0.51) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL10140271 0.80 CNR1 (0.47) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL16258930 0.79 RAB9A (0.52) MEN1KMT2ASMN1; SMN2PTGER4AKR1C3
SCHEMBL10140900 0.79 MAOB (0.40) MEN1KMT2ASMN1; SMN2PTGDR2MAPT
SCHEMBL15946997 0.78 PTGER4 (0.66) MEN1HTTKMT2APTGER4AKR1C3
SCHEMBL8887875 0.77 MEN1 (0.51) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL7977426 0.77 CNR1 (0.48) SMN1; SMN2CNR1CNR2PTGER4FAAH
SCHEMBL10172719 0.77 HDAC1 (0.43) MEN1HTTKMT2ASMN1; SMN2NPSR1
SCHEMBL16258974 0.76 RAB9A (0.43) MEN1HTTKMT2ASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 MEN1 994/4885HTT 3243/4885KMT2A 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.